Private 2RT nanosecond laser for dry AMD

2RT nanosecond laser (retinal rejuvenation therapy) is a low-energy, non-thermal laser being investigated as an early treatment for intermediate dry age-related macular degeneration (AMD). It applies very brief nanosecond pulses to the retinal pigment epithelium (RPE) to prompt a natural cell-renewal response, aiming to slow the disease before vision is lost — without burning the retina. Importantly, the headline clinical trial (LEAD) did not show an overall slowing of progression to late AMD, although a subgroup analysis suggested possible benefit in patients without reticular pseudodrusen and possible harm in those with them. For that reason 2RT remains an emerging, carefully-selected option rather than a proven standard treatment. At our partner clinics it is offered only after a detailed macular assessment, from £395 per session, with the evidence explained honestly so you can make an informed choice.

What is 2RT nanosecond laser and dry AMD?

Dry age-related macular degeneration is the most common form of AMD. It develops slowly as the retinal pigment epithelium — the support layer beneath the light-sensing retina — accumulates waste deposits called drusen and gradually thins. In its intermediate stage there are larger drusen and pigment changes but vision is often still good; the concern is progression to late AMD (geographic atrophy or conversion to wet AMD), which causes central vision loss.

2RT uses a Q-switched, frequency-doubled Nd:YAG laser to deliver energy in nanosecond pulses across a speckled beam. Unlike conventional thermal retinal lasers, the energy is so brief and low that it selectively affects the RPE while sparing the overlying photoreceptors and the deeper Bruch's membrane. The theory is that this triggers a localised healing and rejuvenation response — RPE cells divide and migrate, and the structure of Bruch's membrane may improve — which could, in principle, slow drusen-driven progression.

It is a treatment aimed at the early/intermediate stage, when there is still healthy vision to protect. It is not a treatment for wet AMD (which needs anti-VEGF injections) and it does not restore vision already lost to late AMD.

What the evidence actually shows

Honesty matters with an emerging therapy. The pivotal randomised trial was LEAD (Laser Intervention in Early Stages of AMD), which treated patients with intermediate AMD using 2RT every six months over three years:

• Primary result: across the whole group, 2RT did not significantly slow progression to late AMD compared with sham treatment.
• Subgroup signal: in patients without reticular pseudodrusen, a pre-planned analysis suggested progression may have been slowed.
• Possible harm signal: in patients with reticular pseudodrusen, progression appeared faster after 2RT — so these patients should not be treated.
• Conclusion: the findings are hypothesis-generating. 2RT is not endorsed as a routine, proven treatment for dry AMD, and patient selection is critical.

This is why our approach is conservative: a careful imaging work-up to identify reticular pseudodrusen, a frank discussion of the uncertainty, and ongoing monitoring. If 2RT is not appropriate for you, we will say so and discuss alternatives such as Valeda photobiomodulation, lifestyle and AREDS2 supplementation, and emerging options for geographic atrophy.

Who 2RT may — and may not — suit

2RT is considered only for selected patients with early-stage disease and is decided case by case after imaging.

May be considered if you have:

• Intermediate dry AMD with large drusen but preserved central vision
• No reticular pseudodrusen on imaging
• No geographic atrophy involving the central macula
• A clear understanding that the benefit is unproven and monitoring is essential

Not suitable if you have:

• Reticular pseudodrusen (associated with a possible harm signal)
• Wet (neovascular) AMD — this needs anti-VEGF injection treatment
• Established geographic atrophy with central vision loss
• Other macular disease better treated another way

Learn more about the condition on our dry AMD condition page and macular degeneration treatment overview, and compare the wet and dry pathways in our wet vs dry AMD guide.

What happens during a 2RT session

2RT is a quick outpatient procedure performed in the clinic under anaesthetic eye drops. There are no injections and no surgery.

1. Dilating and numbing drops are given to widen the pupil and anaesthetise the eye surface.
2. A contact lens is placed on the eye to focus the laser onto the retina, as for any retinal laser.
3. The clinician delivers a small number of nanosecond laser applications to the macular area. You may see brief flashes of light; the energy is too low to feel.
4. The lens is removed and your vision is checked. The treatment itself takes only minutes.

Because the disease evolves slowly, treatment is typically planned at intervals (for example every six months in the trial protocol) alongside regular imaging, rather than as a one-off.

Aftercare and monitoring

Recovery is straightforward, but ongoing monitoring is the most important part of dry AMD care.

2RT laser cost

2RT is an elective, self-pay treatment. Because suitability depends on detailed imaging, the fee is confirmed in writing after your macular assessment.

• Macular assessment: a comprehensive OCT and imaging work-up to confirm the stage of AMD and check for reticular pseudodrusen.
• 2RT session: from £395 per session, with the number and interval of sessions planned individually.
• Monitoring: ongoing OCT reviews are quoted separately and are central to safe care.

For other dry AMD and geographic atrophy options and their costs, see Syfovre injection cost and Izervay geographic atrophy injection cost.

Frequently asked questions